472 results about "Fucose" patented technology

A cell in which genome is modified so as to have a more decreased or deleted activity of an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain than its parent cell, and a process for producing an antibody composition using the cell.

The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal β-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.

The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.

The present invention provides a process for producing an antibody composition using a cell, which comprises using a cell into which an RNA having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is introduced; the RNA used in the production process; a DNA corresponding to the RNA; a cell in which the RNA or DNA is introduced or expressed; a process for producing the cell; and a method for suppressing the enzyme.

The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

The invention discloses a method and application for screening an ultralow fucose cell line. The invention provides a method for constructing fucose deficit type host cells capable of expressing an antibody and an IgG-FC fusion protein, a detection method for the fucose activity of the antibody and the IgG-Fc fusion protein, and concrete application of the cell lines. The method provided by the invention is realized by highly-efficient knockout of fucose-based transferase (FUT8) gene in an engineering cell producing the antibodies and the IgG-Fc fusion protein through a TALEN (and/or CRISPR) technology; and through lens culinaris lectin (LCA) pressurizing, gene sequencing and a flow cytometry screening process, the host cells with highly-efficiently knocked-out fucose is obtained. Meanwhile, fucose deficit CHOK1 host cell lines are constructed into stable engineering cell lines capable of expressing antibody proteins; and after the antibody proteins are obtained, glycoform analysis is performed; and results show that fucose knockout efficiency reaches to 99% or above.

The invention discloses establishment and application of a CHO cell line for producing a fucose-free monoclonal antibody. A CRISPR/Cas9 technology is utilized to encode an FUT8 gene of a CHO cell to obtain the FUT8 gene silenced CHO cell line for stabilizing FUT8 gene deletion (hereinafter referred to as FUT8-/-cell line). By adopting physicochemical property and bioactivity detection of an FUT8-/-cell expressed antibody, a glycoform detection result indicates that fucose of the FUT8-/-cell expressed monoclonal antibody is completely eliminated, a fucose-containing monoclonal antibody expressed by a wild CHO cell serves as a contrast, the affinity with a Fcgamma RIIIa antigen of the fucose-free monoclonal antibody is improved by 7 times, and the ADCC effect is improved by 25 times.

A 3-branched asparagine-linked oligosaccharide derivative of the formula (1) wherein the nitrogen of amino group of asparagine is modified with a lipophilic protective group, biotin group or FITC group; a 3-branched asparagine-linked oligosaccharide derivative which contains at least one fucose in N-acetylglucosamine on the nonreducing terminal side of the asparagine-linked oligosaccharide of the derivative; asparagine-linked oligosaccharides and oligosaccharides thereof

wherein Q is a lipophilic protective group, biotin group or FITC group.

A plant cell having an animal-type sugar chain adding function is provided. The plant cell has an introduced gene encoding an enzyme derived from an animal, and the enzyme can transfer a fucose residue to a reducing terminal acetylglucosamine residue of a sugar chan of a glycoprotein.

The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+/-0.3):(1+/-0.3):(3.5+/-0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and/or treating thrombotic diseases.

The invention discloses a skin care composition, wherein the composition mainly comprises the following materials according to parts by weight: 0.1-5 parts of L-fucose, 0.05-5 parts of coenzyme Q10, 0.1-5 parts of hyaluronic acid, 0.05-2 parts of ceramide, and 1-25 parts of mPEG. The skin care composition can be prepared into any common skin care preparation. In addition, the invention further discloses application of the composition in preparation of the skin care composition having the functions of preventing aging and skin inflammation and moisturizing.

The invention discloses a method for determining sea cucumber polysaccharide content in a sea cucumber or a sea cucumber product. The method is characterized in that the sea cucumber or the sea cucumber product is enzymolyzed by protease; the sea cucumber polysaccharide produced by the enzymolysis is separated out by adopting alcohol precipitation; then tested solution is prepared by hydrolysis of trifluoroacetate; the tested solution is prepared into fucose standard water solution which is derived by 1-phenyl-3-methyl-5-pyrazolone; the peak area of fucose derivative in the obtained derivatives is measured by high performance liquid chromatography; and the sea cucumber polysaccharide content in the sea cucumber product is obtained by calculating with the fucose as a reference. The invention provides a simple, accurate, reliable and standardized quantitative analysis method for determining the sea cucumber polysaccharide in various sea cucumbers and sea cucumber products.

The invention discloses low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans (LCRG). The extent of carboxyl reduction is not less than 20%. Weight-average molecular weight of the LCRG is about 3000-20000Da, and monosaccharides comprise acetyl galactosamine (GalNAc), glucose (Glc) or glucuronic acid (GlcUA) and fucose (Fuc) or sulfates of fucose (shown as -OSO3-). The mole ratio of GalNAc, Glc (containing GlcUA), Fuc and -OSO3- is about 1: (1+-0.3): (1+-0.3): (3.0+-1.0). The LCRG is a potent human immunodeficiency virus (HIV) Type 1 entry inhibitor which acts on conserved regions and has the advantages of high activity against HIV Type 1, high therapeutic index and no-drug-resistance, and the LCRG can be used for preventing or curing HIV. The invention further provides a preparation method of the LCRG. The carboxyl-reduced derivatives of fucosylated glycosaminoglycans and medicinal compositions of the carboxyl-reduced derivatives can be prepared into injection agents, lyophilized powder or suppository and the like.

The invention provides a humanized modified anti-CD147 chimeric antibody HcHAb18 and an application thereof. The anti-CD147 human-rat chimeric antibody is prepared on the basis of obtaining hybridoma cells of an anti-human CD147 monoclonal antibody and antibody HcHAb18 genes of the hybridoma cells, wherein the variable region of light chains of the anti-CD147 human-rat chimeric antibody has the amino acid sequence shown in SEQ ID NO:1; the variable region of heavy chains of the anti-CD147 human-rat chimeric antibody has the amino acid sequence shown in SEQ ID NO:2; fucose are not combined in N-acetylglucosamine in a reducing end of a carbohydrate chain at a Fc segment of the anti-CD147 monoclonal antibody in a specific host cell; the glycoform of the anti-CD147 monoclonal antibody is of a mannose type (MAN 5); the anti-CD147 chimeric antibody has antibody dependent cell-mediated cytotoxicity (ADCC). The invention further provides an expression vector and an engineering cell strain of the anti-CD147 chimeric antibody and the application of the anti-CD147 chimeric antibody taken as a cancer treating medicine.